Optimize the cycle of neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: A propensity score matching analysis

被引:29
|
作者
Peng, Hao [1 ]
Chen, Lei [1 ]
Li, Wen-Fei [1 ]
Zhang, Yuan [1 ]
Liu, Li-Zhi [2 ]
Tian, Li [2 ]
Lin, Ai-Hua [3 ]
Sun, Ying [1 ]
Ma, Jun [1 ]
机构
[1] Sun Yat Sen Univ, Dept Radiat Oncol, Ctr Canc, State Key Lab Oncol Southern China,Collaborat Inn, Guangzhou, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Imaging Diag & Intervent Ctr, Ctr Canc, State Key Lab Oncol Southern China,Collaborat Inn, Guangzhou, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Sch Publ Hlth, Dept Med Stat & Epidemiol, Guangzhou, Guangdong, Peoples R China
关键词
Nasopharyngeal carcinoma; Locoregionally advanced; Neoadjuvant chemotherapy; Intensity-modulated radiotherapy; Prognosis; PLUS ADJUVANT CHEMOTHERAPY; PHASE-II TRIAL; CONCURRENT CHEMORADIOTHERAPY; RANDOMIZED-TRIAL; INDUCTION CHEMOTHERAPY; PROGNOSTIC VALUE; CISPLATIN; CARBOPLATIN; SURVIVAL; CANCER;
D O I
10.1016/j.oraloncology.2016.10.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: The aim of this study is to optimize the cycle for patients with locoregionally advanced nasopharyngeal carcinoma (NPC) receiving neoadjuvant chemotherapy (NCT) in the era of intensity-modulated radiotherapy (IMRT). Materials and methods: Data on 569 locoregionally advanced NPC patients treated with IMRT were retrospectively reviewed. Propensity score matching (PSM) method was adopted to balance prognostic factors and match patients. Survival outcomes of matched patients between different NCT cycle groups were compared. Results: The median cycle of NCT was 2 (range, 2-4 cycles) for the whole cohort, and patients were therefore stratified as low cycle (= 2) and high cycle (> 2) groups. In total, 247 pairs of NPC patients were selected by PSM. Univariate analysis found no significantly prognostic difference between the low cycle and high cycle groups, and multivariate analysis did not establish NCT cycle as an independent factor. However, stratified analysis revealed patients in the low cycle group had better OS than those of patients in the high cycle group (92.4% vs. 80.8%, P = 0.029), and NCT was identified as an independent prognostic factor for OS in patients with N2-3 category (HR, 2.252; 95% CI, 1.024-4.953; P = 0.043). Conclusion: Two cycles of NCT may be enough and additional more cycles are not associated with improved survival outcomes for patients with locoregionally advanced NPC in the era of IMRT. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:78 / 84
页数:7
相关论文
共 50 条
  • [41] Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced nasopharyngeal carcinoma: A retrospective propensity score matching analysis
    Tao, Hao-Yun
    Zhan, Ze-Jiang
    Qiu, Wen-Ze
    Liao, Kai
    Yuan, Ya-Wei
    Zheng, Rong-Hui
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (02) : E111 - E118
  • [42] Association of the neoadjuvant chemotherapy cycle with survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: a propensity-matched analysis
    Wang Fangzheng
    Jiang Chuner
    Ye Zhimin
    Sun Quanquan
    Liu Tongxin
    Xu Min
    Wu Peng
    Long Bin
    Sakamoto, Masoto
    Wang Yuezhen
    Yan Fengqin
    Fu Zhenfu
    Jiang Yangming
    [J]. ONCOTARGET, 2017, 8 (55) : 94117 - 94128
  • [43] Weekly versus triweekly cisplatin plus intensity-modulated radiotherapy in locally advanced nasopharyngeal carcinoma: A propensity score analysis with a large cohort
    Zhu, Qian
    Hu, Hao
    Tang, Lin-Quan
    You, Rui
    Zhao, Jing-Jing
    Weng, De-Sheng
    Pan, Qiu-Zhong
    Chen, Chang-Long
    Zhou, Zi-Qi
    Tang, Yan
    Xia, Jian-Chuan
    [J]. JOURNAL OF CANCER, 2018, 9 (19): : 3447 - 3455
  • [44] A Multicentre UK Study of Outcomes of Nasopharyngeal Carcinoma Treated With Intensity-Modulated Radiotherapy ± Chemotherapy
    Slevin, F.
    Pan, S.
    Mistry, H.
    Sen, M.
    Foran, B.
    Slevin, N.
    Dixon, L.
    Thomson, D.
    Prestwich, R.
    [J]. CLINICAL ONCOLOGY, 2020, 32 (04) : 238 - 249
  • [45] Nasopharyngeal carcinoma with intracranial extension in the era of intensity-modulated radiotherapy: case–control study using propensity score matching method
    Cai-neng Cao
    Jing-wei Luo
    Li Gao
    Guo-zhen Xu
    Jun-lin Yi
    Xiao-dong Huang
    Su-yan Li
    Jian-ping Xiao
    Zhong Zhang
    [J]. European Archives of Oto-Rhino-Laryngology, 2016, 273 : 2209 - 2215
  • [46] Nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: CAMS experience
    Yi, J.
    Gao, L.
    Huang, X.
    Luo, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] Outcomes of patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy
    Yeh, Shyh-An
    Hwang, Tzer-Zen
    Wang, Chih-Chun
    Yang, Chuen-Chien
    Lien, Ching-Feng
    Wang, Chien-Chung
    Hsu, Tun-Yen
    Hsu, Ruey-Feng
    Shih, Yu-Chen
    Huang, Yaw-Chang
    Hsieh, Meng-Che
    Gau, Jhy-Shyan
    Chang, Liyun
    Lee, Tsair-Fwu
    [J]. JOURNAL OF RADIATION RESEARCH, 2021, 62 (03) : 438 - 447
  • [48] Experience of weekly cisplatin concurrent with intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma patients with resistance to neoadjuvant chemotherapy
    Chen, Chuanben
    Chen, Taojun
    Huang, Chaoxiong
    Wang, Jing
    Fei, Zhaodong
    [J]. MEDICINE, 2017, 96 (44)
  • [49] Outcomes of patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy
    Department of Radiation Oncology, E-DA Hospital, Kaohsiung City, Taiwan
    不详
    不详
    不详
    不详
    不详
    不详
    [J]. J. Rad. Res., 1600, 3 (438-447):
  • [50] Concurrent Chemotherapy and Intensity-Modulated Radiotherapy for Locoregionally Advanced Laryngeal and Hypopharyngeal Cancers
    Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, United States
    不详
    不详
    不详
    [J]. Int. J. Radiat. Oncol. Biol. Phys., 2 (459-468):